Latest News about BMRN
Recent news which mentions BMRN
   BioMarin's Roctavian US Launch: Focus on Commercial Strategy Amid EU Failures, Analyst Points Out
   
  June 30, 2023
  Tickers 
   BMRN
  
  
  From Benzinga
 From Benzinga
 From Benzinga
 
   3 Biotech Stocks to Buy With Explosive Upside Potential
   
  
  
  June 22, 2023
  From InvestorPlace
 From InvestorPlace
 From MarketWatch
 From Benzinga
 From Benzinga
 
   3 Biotech Stocks With Blockbuster Potential
   
  
  
  May 24, 2023
  From InvestorPlace
 
   A volatile summer is coming as Fed pause, debt tussle meet. Shelter in these stocks, says strategist
   
  
  
  May 01, 2023
  From MarketWatch
 
   10 Health Care Stocks With Whale Alerts In Today's Session
   
  
  
  April 20, 2023
  From Benzinga
 
   7 Biotech Stocks That Could Cure Your Portfolio Woes
   
  
  
  April 19, 2023
  From InvestorPlace
 From Motley Fool
 From Benzinga
 
   After FDA Delays Hemophilia Gene Therapy, BioMarin's Dwarfism Drug Under FDA Review For Expanded Use
   
  
  
  March 08, 2023
  From Benzinga
 
   Why BioMarin Shares Are Plunging Today?
   
  
  
  March 06, 2023
  From Benzinga
 
   BioMarin Hints Probable Delay For US Approval For Roctavian, But Analyst Convinced For Transformative 2023
   
  February 28, 2023
  Tickers 
   BMRN
  
  
  From Benzinga
 
   Earnings Scheduled For February 27, 2023
   
  
  
  February 27, 2023
  From Benzinga
 
   Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023
   
  
  
  February 22, 2023
  From Benzinga
 
   Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
   
  
  
  February 21, 2023
  From Benzinga
 
   3 Prime Healthcare Takeover Targets
   
  
  
  February 14, 2023
  From Motley Fool
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.